thymidine has been researched along with Complications, Infectious Pregnancy in 46 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Administration of telbivudine to HBV-infected mothers, started during early and middle pregnancy, completely blocked mother-to-infant HBV transmission." | 9.24 | Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmission. ( Hao, A; Li, F; Ma, L; Song, M; Sun, W; Zhao, B; Zhao, S; Zhou, L, 2017) |
| "None of the infants whose mothers were given telbivudine tested positive for of hepatitis B surface antigen at 6 months, compared with 14." | 9.20 | Telbivudine prevents vertical transmission of hepatitis B virus from women with high viral loads: a prospective long-term study. ( Deng, G; He, D; He, Y; Huang, H; Li, J; Li, L; Pan, M; Sun, X; Tan, S; Wang, Y; Wu, Q; Yan, Z; Zeng, Y, 2015) |
| "Little observational data exist describing telbivudine (LdT) or lamivudine (LAM) use in late pregnancy for preventing hepatitis B mother-to-child transmission (MTCT) in real-world settings." | 9.19 | Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. ( Liu, X; Pan, CQ; Pang, Q; Tian, R; Yan, M; Zhang, H, 2014) |
| "To observe the long-term efficacy and safety of telbivudine (LdT) for pregnant women with chronic hepatitis B (CHB) and their children born from the treatment period." | 9.19 | [Long-term efficacy and safety of telbivudine in the treatment of childbearing patients with chronic hepatitis B]. ( Lu, C; Pan, H; Zheng, J; Zhou, Y, 2014) |
| " In recent years, there have been gradually increasing reports on the safety of telbivudine (LdT) treatment for chronic hepatitis B virus (HBV) infection in the third trimester of pregnancy to block mother-to-infant transmission (MTIT) of HBV; however, the safety of LdT treatment for chronic HBV infection for the entire pregnancy has not been reported." | 9.17 | Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy. ( Cai, H; Liu, M; Yi, W, 2013) |
| "Telbivudine use during the second and third trimester of pregnancy in HBeAg+ highly viremic mothers can safely reduce perinatal HBV transmission rates." | 9.16 | [Efficacy and safety of telbivudine in pregnant women to prevent perinatal transmission of hepatitis B virus]. ( Han, GR; Jiang, HX; Kan, NY; Wang, CM; Wang, GJ; Wu, MM; Yue, X, 2012) |
| "Women with CHB given telbivudine during the second or third trimester of pregnancy have reduced rates of perinatal transmission." | 9.16 | Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. ( Cao, MK; Han, GR; Jiang, HX; Pan, CQ; Wang, CM; Wang, GJ; Yue, X; Zhao, W, 2012) |
| "Telbivudine used during pregnancy in CHB HBeAg+highly viremic mothers can safely reduce perinatal HBV transmission." | 9.15 | A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. ( Bai, SF; Cao, MK; Fang, ZX; Han, GR; Jiang, HX; Tang, X; Wang, CM; Wang, GJ; Yue, X; Zhao, W, 2011) |
| "To investigate the efficacy of telbivudine on intrauterine hepatitis B virus (HBV) infection during the last stage of pregnancy." | 9.14 | [Blocking intrauterine infection by telbivudine in pregnant chronic hepatitis B patients]. ( Wang, L; Zhang, LJ, 2009) |
| " The antiviral efficacy and safety of telbivudine (LdT) have been shown in patients with CHB infection, and LdT is approved as a class B drug for pregnancy." | 8.95 | Telbivudine therapy for gravidas with chronic hepatitis B infection and patients at risk of renal impairment. ( Chen, T; Liu, J; Zhao, Y, 2017) |
| "Telbivudine, one of the oral anti-hepatitis B virus (HBV) nucleoside analogues, has been used for more than 5 years to treat HBeAg-positive and -negative chronic hepatitis B (CHB) patients." | 8.89 | Telbivudine treatment in chronic hepatitis B: experience from China. ( Jia, J; You, H, 2013) |
| "To investigate postpartum hepatic flares and associated factors in highly viremic pregnant patients in the immune tolerance phase who adopted telbivudine (LdT) treatment in the last trimester to reduce vertical transmission of hepatitis B virus." | 8.02 | Clinical and Immunological Factors Associated with Postpartum Hepatic Flares in Immune-Tolerant Pregnant Women with Hepatitis B Virus Infection Treated with Telbivudine. ( Chen, X; Hu, Z; Lu, J; Ma, L; Wang, X; Zheng, S; Zhu, Y, 2021) |
| "Treatment with lamivudine or telbivudine for active CHB in early pregnancy appears to be safe and effective for controlling maternal disease as well as interrupting MTCT." | 7.88 | Safety and efficacy of lamivudine or telbivudine started in early pregnancy for mothers with active chronic hepatitis B. ( Bai, Y; Cai, H; He, T; Jia, J; Liu, M; Ou, X; Yi, W, 2018) |
| "Telbivudine, an FDA pregnancy category B drug, has been found to reduce hepatitis B virus (HBV) perinatal transmission with no safety concerns in infants aged up to 1 year." | 7.85 | Long-term safety and efficacy of telbivudine in infants born to mothers treated during the second or third trimesters of pregnancy. ( Ding, Y; Han, GR; Jiang, HX; Wang, CM; Wang, GJ; Yue, X; Zhao, W; Zhou, L, 2017) |
| "Chronic hepatitis B virus-infected women who received telbivudine beginning at week 24 or 28 of gestation were enrolled and then followed up to 52 weeks postpartum." | 7.85 | Hepatic flare after telbivudine withdrawal and efficacy of postpartum antiviral therapy for pregnancies with chronic hepatitis B virus. ( Cao, F; Chen, T; Feng, W; Guo, D; Jin, D; Jin, L; Liu, J; Qi, C; Tian, Z; Wang, J; Yan, T; Yuan, N; Zhang, S; Zhao, Y, 2017) |
| "To observe the success rate of telbivudine (LdT) for the prevention of perinatal transmission of hepatitis B virus (HBV) and the incidence of alanine aminotransferase (ALT) elevation during LdT treatment and after LdT withdrawal in HBV-infected pregnant woman with high viremia in immune-tolerant phase and receiving LdT treatment at the end of pregnancy, and to evaluate the efficacy of LdT in the prevention of perinatal transmission and the safety for pregnant women." | 7.83 | [Telbivudine for prevention of perinatal transmission in pregnant women infected with hepatitis B virus in immune-tolerant phase: a study of efficacy and safety of drug withdrawal]. ( Bai, H; Ding, Y; Dou, XG; Fan, YX; Han, C; Li, BJ; Li, YW; Sheng, QJ; Zhang, C, 2016) |
| "The growth and development of children prenatally exposed to telbivudine was normal, indicating that telbivudine treatment during pregnancy is safe and effective." | 7.81 | Growth and development of children prenatally exposed to telbivudine administered for the treatment of chronic hepatitis B in their mothers. ( Cai, H; Shen, Y; Wang, Y; Zeng, H, 2015) |
| "To investigate the efficacy and safety of telbivudine for blocking mother-to-child transmission of hepatitis B virus (HBV) in pregnant women with high viremia." | 7.81 | [Predictive value of telbivudine in preventing mother-to-infant transmission of hepatitis B virus in pregnant women with high viremia]. ( Hao, A; Li, M; Liu, W; Ma, L; Song, M; Sun, W; Xin, Y, 2015) |
| "To explore the antiviral efficacy, safety and protective ability against mother-to-infant transmission of telbivudine in pregnant patients with chronic hepatitis B (CHB) during the first trimester." | 7.81 | [Clinical observation of telbivudine's antiviral efficacy and protection against mother-to-infant transmission of chronic hepatitis B during the first trimester of pregnancy]. ( Chen, C; Chen, F; Cheng, Q; Dai, Y; Gong, F; Lin, X; Tu, X, 2015) |
| " These pregnant females developed lamivudine (LAM)- or telbivudine (LdT)-resistant chronic hepatitis B and received tenofovir (TDF) therapy (300 mg/d), and its curative effect, maternal and perinatal adverse events, fetal growth and development, and neonatal prognosis were evaluated." | 7.81 | Tenofovir rescue therapy in pregnant females with chronic hepatitis B. ( Cai, HD; Cao, YJ; Hu, YH; Liu, M; Yi, W, 2015) |
| "The outcome of neonatal herpes simplex (HSV) infection, even after therapy with high dose acyclovir (ACV), is not optimum." | 7.77 | N-Methanocarbathymidine is more effective than acyclovir for treating neonatal herpes simplex virus infection in guinea pigs. ( Bernstein, DI; Bravo, FJ; Cardin, RD; Clark, JR; Earwood, JD; Glazer, R; Rahman, A, 2011) |
| "Telbivudine is a synthetic thymidine nucleoside analogue with activity against HBV." | 6.48 | The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis. ( Chen, HZ; Deng, M; Gao, S; Ruan, B; Wang, B; Yang, SG; Zhou, X, 2012) |
| " In addition, adverse events regarding infants at delivery and HBV vaccination outcomes were recorded." | 5.46 | Safety and efficacy of telbivudine for chronic hepatitis B during the entire pregnancy: Long-term follow-up. ( Bai, L; Liu, K; Shang, J; Tang, H; Wang, CC; Wen, Q, 2017) |
| "Administration of telbivudine to HBV-infected mothers, started during early and middle pregnancy, completely blocked mother-to-infant HBV transmission." | 5.24 | Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmission. ( Hao, A; Li, F; Ma, L; Song, M; Sun, W; Zhao, B; Zhao, S; Zhou, L, 2017) |
| "None of the infants whose mothers were given telbivudine tested positive for of hepatitis B surface antigen at 6 months, compared with 14." | 5.20 | Telbivudine prevents vertical transmission of hepatitis B virus from women with high viral loads: a prospective long-term study. ( Deng, G; He, D; He, Y; Huang, H; Li, J; Li, L; Pan, M; Sun, X; Tan, S; Wang, Y; Wu, Q; Yan, Z; Zeng, Y, 2015) |
| "To observe the long-term efficacy and safety of telbivudine (LdT) for pregnant women with chronic hepatitis B (CHB) and their children born from the treatment period." | 5.19 | [Long-term efficacy and safety of telbivudine in the treatment of childbearing patients with chronic hepatitis B]. ( Lu, C; Pan, H; Zheng, J; Zhou, Y, 2014) |
| "Little observational data exist describing telbivudine (LdT) or lamivudine (LAM) use in late pregnancy for preventing hepatitis B mother-to-child transmission (MTCT) in real-world settings." | 5.19 | Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. ( Liu, X; Pan, CQ; Pang, Q; Tian, R; Yan, M; Zhang, H, 2014) |
| " In recent years, there have been gradually increasing reports on the safety of telbivudine (LdT) treatment for chronic hepatitis B virus (HBV) infection in the third trimester of pregnancy to block mother-to-infant transmission (MTIT) of HBV; however, the safety of LdT treatment for chronic HBV infection for the entire pregnancy has not been reported." | 5.17 | Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy. ( Cai, H; Liu, M; Yi, W, 2013) |
| "Women with CHB given telbivudine during the second or third trimester of pregnancy have reduced rates of perinatal transmission." | 5.16 | Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. ( Cao, MK; Han, GR; Jiang, HX; Pan, CQ; Wang, CM; Wang, GJ; Yue, X; Zhao, W, 2012) |
| "Telbivudine use during the second and third trimester of pregnancy in HBeAg+ highly viremic mothers can safely reduce perinatal HBV transmission rates." | 5.16 | [Efficacy and safety of telbivudine in pregnant women to prevent perinatal transmission of hepatitis B virus]. ( Han, GR; Jiang, HX; Kan, NY; Wang, CM; Wang, GJ; Wu, MM; Yue, X, 2012) |
| "Telbivudine used during pregnancy in CHB HBeAg+highly viremic mothers can safely reduce perinatal HBV transmission." | 5.15 | A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. ( Bai, SF; Cao, MK; Fang, ZX; Han, GR; Jiang, HX; Tang, X; Wang, CM; Wang, GJ; Yue, X; Zhao, W, 2011) |
| "To investigate the efficacy of telbivudine on intrauterine hepatitis B virus (HBV) infection during the last stage of pregnancy." | 5.14 | [Blocking intrauterine infection by telbivudine in pregnant chronic hepatitis B patients]. ( Wang, L; Zhang, LJ, 2009) |
| " US FDA pregnancy category B agents such as tenofovir and telbivudine are allowed through all trimesters of pregnancy." | 4.95 | Hepatitis B During Pregnancy in Endemic Areas: Screening, Treatment, and Prevention of Mother-to-Child Transmission. ( Chamroonkul, N; Piratvisuth, T, 2017) |
| " The antiviral efficacy and safety of telbivudine (LdT) have been shown in patients with CHB infection, and LdT is approved as a class B drug for pregnancy." | 4.95 | Telbivudine therapy for gravidas with chronic hepatitis B infection and patients at risk of renal impairment. ( Chen, T; Liu, J; Zhao, Y, 2017) |
| "Telbivudine, one of the oral anti-hepatitis B virus (HBV) nucleoside analogues, has been used for more than 5 years to treat HBeAg-positive and -negative chronic hepatitis B (CHB) patients." | 4.89 | Telbivudine treatment in chronic hepatitis B: experience from China. ( Jia, J; You, H, 2013) |
| "Telbivudine treatment effectively and safely prevents mother-to-child transmission of HBV from chronically infected mothers with a high degree of infectivity late in pregnancy." | 4.88 | [Efficacy and safety of telbivudine treatment to block mother-to-child transmission of hepatitis B virus: a meta-analysis]. ( Chen, Y; Liu, XX; Wang, LJ; Wu, YP; Xu, HX; Xu, YF; Yu, YX, 2012) |
| "To investigate postpartum hepatic flares and associated factors in highly viremic pregnant patients in the immune tolerance phase who adopted telbivudine (LdT) treatment in the last trimester to reduce vertical transmission of hepatitis B virus." | 4.02 | Clinical and Immunological Factors Associated with Postpartum Hepatic Flares in Immune-Tolerant Pregnant Women with Hepatitis B Virus Infection Treated with Telbivudine. ( Chen, X; Hu, Z; Lu, J; Ma, L; Wang, X; Zheng, S; Zhu, Y, 2021) |
| "Treatment with lamivudine or telbivudine for active CHB in early pregnancy appears to be safe and effective for controlling maternal disease as well as interrupting MTCT." | 3.88 | Safety and efficacy of lamivudine or telbivudine started in early pregnancy for mothers with active chronic hepatitis B. ( Bai, Y; Cai, H; He, T; Jia, J; Liu, M; Ou, X; Yi, W, 2018) |
| "Chronic hepatitis B virus-infected women who received telbivudine beginning at week 24 or 28 of gestation were enrolled and then followed up to 52 weeks postpartum." | 3.85 | Hepatic flare after telbivudine withdrawal and efficacy of postpartum antiviral therapy for pregnancies with chronic hepatitis B virus. ( Cao, F; Chen, T; Feng, W; Guo, D; Jin, D; Jin, L; Liu, J; Qi, C; Tian, Z; Wang, J; Yan, T; Yuan, N; Zhang, S; Zhao, Y, 2017) |
| "Telbivudine, an FDA pregnancy category B drug, has been found to reduce hepatitis B virus (HBV) perinatal transmission with no safety concerns in infants aged up to 1 year." | 3.85 | Long-term safety and efficacy of telbivudine in infants born to mothers treated during the second or third trimesters of pregnancy. ( Ding, Y; Han, GR; Jiang, HX; Wang, CM; Wang, GJ; Yue, X; Zhao, W; Zhou, L, 2017) |
| "To observe the success rate of telbivudine (LdT) for the prevention of perinatal transmission of hepatitis B virus (HBV) and the incidence of alanine aminotransferase (ALT) elevation during LdT treatment and after LdT withdrawal in HBV-infected pregnant woman with high viremia in immune-tolerant phase and receiving LdT treatment at the end of pregnancy, and to evaluate the efficacy of LdT in the prevention of perinatal transmission and the safety for pregnant women." | 3.83 | [Telbivudine for prevention of perinatal transmission in pregnant women infected with hepatitis B virus in immune-tolerant phase: a study of efficacy and safety of drug withdrawal]. ( Bai, H; Ding, Y; Dou, XG; Fan, YX; Han, C; Li, BJ; Li, YW; Sheng, QJ; Zhang, C, 2016) |
| "To explore the antiviral efficacy, safety and protective ability against mother-to-infant transmission of telbivudine in pregnant patients with chronic hepatitis B (CHB) during the first trimester." | 3.81 | [Clinical observation of telbivudine's antiviral efficacy and protection against mother-to-infant transmission of chronic hepatitis B during the first trimester of pregnancy]. ( Chen, C; Chen, F; Cheng, Q; Dai, Y; Gong, F; Lin, X; Tu, X, 2015) |
| " These pregnant females developed lamivudine (LAM)- or telbivudine (LdT)-resistant chronic hepatitis B and received tenofovir (TDF) therapy (300 mg/d), and its curative effect, maternal and perinatal adverse events, fetal growth and development, and neonatal prognosis were evaluated." | 3.81 | Tenofovir rescue therapy in pregnant females with chronic hepatitis B. ( Cai, HD; Cao, YJ; Hu, YH; Liu, M; Yi, W, 2015) |
| "To investigate the efficacy and safety of telbivudine for blocking mother-to-child transmission of hepatitis B virus (HBV) in pregnant women with high viremia." | 3.81 | [Predictive value of telbivudine in preventing mother-to-infant transmission of hepatitis B virus in pregnant women with high viremia]. ( Hao, A; Li, M; Liu, W; Ma, L; Song, M; Sun, W; Xin, Y, 2015) |
| "Use of telbivudine antiviral therapy during late pregnancy in women with high-load HBV DNA can significantly reduce level of HBV DNA in maternal peripheral blood, block HBV intrauterine transmission, and provide good short-term efficacy, with good tolerability and safety." | 3.81 | [The safety of telbivudine in preventing mother-to-infant transmission of hepatitis B virus in pregnant women after discontinuation]. ( Deng, Y; Hu, P; Kang, J; Wu, W; Yang, Y; Zeng, W; Zhang, D, 2015) |
| "To observe the clinical efficacy of combination therapy with peg-IFNalpha and adefovir (CPIA) in women who were hepatfis B virus (HBV) carriers and had just given birth and received telbivudine (LdT) during pregnancy for prevention of mother-to-child transmission." | 3.81 | [Efficacy of combination antiviral therapy following childbirth in pregnant HBV carriers receiving telbivudine for prevention of mother-to-child transmission]. ( Cao, ZH; Chen, XY; He, ZM; Jin, Y; Liu, YL; Lu, JF; Ma, LN; Zhang, SB, 2015) |
| "The growth and development of children prenatally exposed to telbivudine was normal, indicating that telbivudine treatment during pregnancy is safe and effective." | 3.81 | Growth and development of children prenatally exposed to telbivudine administered for the treatment of chronic hepatitis B in their mothers. ( Cai, H; Shen, Y; Wang, Y; Zeng, H, 2015) |
| "The outcome of neonatal herpes simplex (HSV) infection, even after therapy with high dose acyclovir (ACV), is not optimum." | 3.77 | N-Methanocarbathymidine is more effective than acyclovir for treating neonatal herpes simplex virus infection in guinea pigs. ( Bernstein, DI; Bravo, FJ; Cardin, RD; Clark, JR; Earwood, JD; Glazer, R; Rahman, A, 2011) |
| "Telbivudine is a synthetic thymidine nucleoside analogue with activity against HBV." | 2.48 | The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis. ( Chen, HZ; Deng, M; Gao, S; Ruan, B; Wang, B; Yang, SG; Zhou, X, 2012) |
| " LdT treatment during pregnancy is safe for both mothers and infants in the long term." | 1.91 | Efficacy and Long-term Safety of Telbivudine Usage During Second or Third Trimester in Hepatitis B Surface Antigen Positive Mothers With High Viral Load: A 10-year Prospective Study. ( Chen, C; Han, G; Jiang, H; Ye, X; Zhou, G, 2023) |
| " In addition, adverse events regarding infants at delivery and HBV vaccination outcomes were recorded." | 1.46 | Safety and efficacy of telbivudine for chronic hepatitis B during the entire pregnancy: Long-term follow-up. ( Bai, L; Liu, K; Shang, J; Tang, H; Wang, CC; Wen, Q, 2017) |
| "New insights into the treatment of chronic hepatitis B with relevance for clinical practice have been adopted in these concise, revised guidelines." | 1.38 | The 2012 revised Dutch national guidelines for the treatment of chronic hepatitis B virus infection. ( Baak, BC; Bakker, CM; Beuers, UH; Brouwer, JT; Buster, EH; Drenth, JP; Honkoop, P; Janssen, HL; Kerbert-Dreteler, MJ; Koek, GH; Tan, AC; van der Spek, BW; van Erpecum, KJ; van Hoek, B; van Nieuwkerk, KM; van Soest, H; Vrolijk, JM, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.17) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (4.35) | 29.6817 |
| 2010's | 41 (89.13) | 24.3611 |
| 2020's | 2 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, H | 1 |
| Ye, X | 1 |
| Chen, C | 2 |
| Zhou, G | 1 |
| Han, G | 1 |
| Lu, J | 1 |
| Wang, X | 1 |
| Zhu, Y | 1 |
| Ma, L | 3 |
| Zheng, S | 1 |
| Hu, Z | 1 |
| Chen, X | 1 |
| Sun, W | 2 |
| Zhao, S | 1 |
| Hao, A | 2 |
| Zhao, B | 1 |
| Zhou, L | 2 |
| Li, F | 1 |
| Song, M | 2 |
| Chamroonkul, N | 1 |
| Piratvisuth, T | 1 |
| Shang, J | 1 |
| Wen, Q | 1 |
| Wang, CC | 1 |
| Liu, K | 1 |
| Bai, L | 1 |
| Tang, H | 1 |
| Liu, J | 2 |
| Chen, T | 2 |
| Zhao, Y | 2 |
| He, T | 1 |
| Bai, Y | 1 |
| Cai, H | 3 |
| Ou, X | 1 |
| Liu, M | 3 |
| Yi, W | 3 |
| Jia, J | 2 |
| Sheng, QJ | 2 |
| Wang, SJ | 1 |
| Wu, YY | 1 |
| Dou, XG | 2 |
| Ding, Y | 3 |
| You, H | 1 |
| Sarkar, M | 1 |
| Terrault, NA | 1 |
| Yu, MM | 1 |
| Jiang, Q | 1 |
| Ji, Y | 1 |
| Wu, KH | 1 |
| Ju, LL | 1 |
| Tang, X | 2 |
| Yang, YF | 1 |
| Gerlich, WH | 1 |
| Zhang, H | 1 |
| Pan, CQ | 2 |
| Pang, Q | 1 |
| Tian, R | 1 |
| Yan, M | 1 |
| Liu, X | 1 |
| Dunkelberg, JC | 1 |
| Berkley, EM | 1 |
| Thiel, KW | 1 |
| Leslie, KK | 1 |
| Zhou, Y | 1 |
| Zheng, J | 1 |
| Pan, H | 1 |
| Lu, C | 1 |
| Wu, Q | 1 |
| Huang, H | 1 |
| Sun, X | 1 |
| Pan, M | 1 |
| He, Y | 1 |
| Tan, S | 1 |
| Zeng, Y | 1 |
| Li, L | 1 |
| Deng, G | 1 |
| Yan, Z | 1 |
| He, D | 1 |
| Li, J | 1 |
| Wang, Y | 2 |
| Zeng, H | 1 |
| Shen, Y | 1 |
| Hollinger, FB | 1 |
| Hu, YH | 1 |
| Cao, YJ | 1 |
| Cai, HD | 1 |
| Tu, X | 1 |
| Cheng, Q | 1 |
| Chen, F | 1 |
| Dai, Y | 1 |
| Gong, F | 1 |
| Lin, X | 1 |
| Liu, W | 1 |
| Li, M | 1 |
| Xin, Y | 1 |
| El Agheb, MO | 1 |
| Grange, JD | 1 |
| Njei, B | 1 |
| Gupta, N | 1 |
| Ewelukwa, O | 1 |
| Ditah, I | 1 |
| Foma, M | 1 |
| Lim, JK | 1 |
| Deng, Y | 1 |
| Wu, W | 1 |
| Zhang, D | 1 |
| Hu, P | 1 |
| Kang, J | 1 |
| Yang, Y | 1 |
| Zeng, W | 1 |
| Lu, JF | 1 |
| Liu, YL | 1 |
| Ma, LN | 1 |
| Cao, ZH | 1 |
| He, ZM | 1 |
| Jin, Y | 1 |
| Zhang, SB | 1 |
| Chen, XY | 1 |
| Wang, J | 1 |
| Jin, D | 1 |
| Qi, C | 1 |
| Yan, T | 1 |
| Cao, F | 1 |
| Jin, L | 1 |
| Tian, Z | 1 |
| Guo, D | 1 |
| Yuan, N | 1 |
| Feng, W | 1 |
| Zhang, S | 1 |
| Li, BJ | 1 |
| Bai, H | 1 |
| Zhang, C | 1 |
| Han, C | 1 |
| Fan, YX | 1 |
| Li, YW | 1 |
| Tan, Z | 1 |
| Yin, Y | 1 |
| Zhou, J | 1 |
| Wu, L | 1 |
| Xu, C | 1 |
| Hou, H | 1 |
| Han, GR | 4 |
| Jiang, HX | 4 |
| Wang, CM | 4 |
| Wang, GJ | 4 |
| Yue, X | 4 |
| Zhao, W | 3 |
| Galegov, GA | 1 |
| Zhang, LJ | 1 |
| Wang, L | 1 |
| But, DY | 1 |
| Yuen, MF | 1 |
| Fung, J | 1 |
| Lai, CL | 1 |
| Cao, MK | 2 |
| Bai, SF | 1 |
| Fang, ZX | 1 |
| Petersen, J | 1 |
| Giles, M | 1 |
| Visvanathan, K | 1 |
| Sasadeusz, J | 1 |
| Bernstein, DI | 1 |
| Bravo, FJ | 1 |
| Clark, JR | 1 |
| Earwood, JD | 1 |
| Rahman, A | 1 |
| Glazer, R | 1 |
| Cardin, RD | 1 |
| Kan, NY | 1 |
| Wu, MM | 1 |
| Dusheiko, G | 1 |
| Zhou, YJ | 1 |
| Zheng, JL | 1 |
| Pan, HJ | 1 |
| Jiang, S | 1 |
| Deng, M | 1 |
| Zhou, X | 1 |
| Gao, S | 1 |
| Yang, SG | 1 |
| Wang, B | 1 |
| Chen, HZ | 1 |
| Ruan, B | 1 |
| Buster, EH | 1 |
| Baak, BC | 1 |
| Bakker, CM | 1 |
| Beuers, UH | 1 |
| Brouwer, JT | 1 |
| Drenth, JP | 1 |
| van Erpecum, KJ | 1 |
| van Hoek, B | 1 |
| Honkoop, P | 1 |
| Kerbert-Dreteler, MJ | 1 |
| Koek, GH | 1 |
| van Nieuwkerk, KM | 1 |
| van Soest, H | 1 |
| van der Spek, BW | 1 |
| Tan, AC | 1 |
| Vrolijk, JM | 1 |
| Janssen, HL | 1 |
| Xu, HX | 1 |
| Wang, LJ | 1 |
| Yu, YX | 1 |
| Wu, YP | 1 |
| Xu, YF | 1 |
| Liu, XX | 1 |
| Chen, Y | 1 |
| Chen, R | 1 |
| Liu, SR | 1 |
| Zhang, SY | 1 |
| Tao, CJ | 1 |
| Simons, MJ | 1 |
| Fitzgerald, MG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy and Safety of Telbivudine and Lamivudine Use in Highly Viremic Mothers to Prevent Hepatitis B Transmission[NCT01743079] | Phase 4 | 700 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Study of Efficacy and Safety of Telbivudine in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus Infection[NCT00939068] | Phase 4 | 180 participants (Anticipated) | Interventional | 2008-02-29 | Enrolling by invitation | ||
| The Effect of Telbivudine on Renal Function and Proteinuria in Patients With Chronic Hepatitis B Infection and Chronic Kidney Diseases[NCT02049736] | 0 participants (Actual) | Interventional | 2013-12-31 | Withdrawn (stopped due to unable to recruit patients) | |||
| Telbivudine in the Third Trimester of Pregnancy to Prevent Mother-to-infant Transmission of HBV[NCT01637844] | Phase 4 | 335 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| [NCT01337791] | Phase 4 | 88 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for thymidine and Complications, Infectious Pregnancy
| Article | Year |
|---|---|
Hepatitis B During Pregnancy in Endemic Areas: Screening, Treatment, and Prevention of Mother-to-Child Transmission.
Topics: Antiviral Agents; Endemic Diseases; Female; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Ch | 2017 |
Telbivudine therapy for gravidas with chronic hepatitis B infection and patients at risk of renal impairment.
Topics: Animals; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Pregnancy; Pregnancy Complications, | 2017 |
Telbivudine treatment in chronic hepatitis B: experience from China.
Topics: Antiviral Agents; China; Clinical Trials as Topic; Female; Hepatitis B e Antigens; Hepatitis B virus | 2013 |
Hepatitis B and C in pregnancy: a review and recommendations for care.
Topics: Antiviral Agents; Breast Feeding; Cesarean Section; Contraindications; DNA, Viral; Female; Hepatitis | 2014 |
Comparative efficacy of antiviral therapy in preventing vertical transmission of hepatitis B: a network meta-analysis.
Topics: Antiviral Agents; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; H | 2016 |
[Highly efficient chemoprophylaxis of perinatal transmission of HIV 1 infection in HIV-infected pregnant women].
Topics: Animals; Anti-HIV Agents; Azides; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, | 2009 |
Safety evaluation of telbivudine.
Topics: Adult; Antiviral Agents; Biomarkers; Creatine Kinase; Double-Blind Method; Drug Resistance, Viral; F | 2010 |
Antiviral therapy for hepatitis B infection during pregnancy and breastfeeding.
Topics: Adenine; Antiviral Agents; Breast Feeding; Female; Guanine; Hepatitis B; Hepatitis B virus; Hepatiti | 2011 |
The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis.
Topics: Antiviral Agents; Female; Hepatitis B Antibodies; Hepatitis B, Chronic; Humans; Infectious Disease T | 2012 |
[Efficacy and safety of telbivudine treatment to block mother-to-child transmission of hepatitis B virus: a meta-analysis].
Topics: Antiviral Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infectious Diseas | 2012 |
11 trials available for thymidine and Complications, Infectious Pregnancy
| Article | Year |
|---|---|
Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmission.
Topics: Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Hepatitis B Surface Antigens; Hep | 2017 |
Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy.
Topics: Adult; Antiviral Agents; China; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Inf | 2013 |
Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice.
Topics: Adult; Antiviral Agents; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Anti | 2014 |
[Long-term efficacy and safety of telbivudine in the treatment of childbearing patients with chronic hepatitis B].
Topics: Adolescent; Adult; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Infant; Infant, Newborn; | 2014 |
Telbivudine prevents vertical transmission of hepatitis B virus from women with high viral loads: a prospective long-term study.
Topics: Adolescent; Adult; Antiviral Agents; China; DNA, Viral; Female; Hepatitis B; Hepatitis B Surface Ant | 2015 |
[Blocking intrauterine infection by telbivudine in pregnant chronic hepatitis B patients].
Topics: Administration, Oral; Antiviral Agents; DNA, Viral; Female; Hepatitis B Surface Antigens; Hepatitis | 2009 |
A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatit | 2011 |
Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Case-Control Studies; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis | 2012 |
Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Case-Control Studies; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis | 2012 |
Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Case-Control Studies; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis | 2012 |
Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Case-Control Studies; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis | 2012 |
[Efficacy and safety of telbivudine in pregnant women to prevent perinatal transmission of hepatitis B virus].
Topics: Adult; DNA, Viral; Female; Hepatitis B; Hepatitis B virus; Humans; Infectious Disease Transmission, | 2012 |
[Efficacy and safety of telbivudine in pregnant chronic hepatitis B patients].
Topics: Adult; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Nucleosides; Pregnancy; Pregnancy Com | 2011 |
[Efficacy of telbivudine in blocking the vertical transmission and the safety observation of discontinuing treatment time after delivery on mother infected with HBV].
Topics: Adult; Antiviral Agents; Female; Hepatitis B; Humans; Infectious Disease Transmission, Vertical; Mot | 2012 |
25 other studies available for thymidine and Complications, Infectious Pregnancy
| Article | Year |
|---|---|
Efficacy and Long-term Safety of Telbivudine Usage During Second or Third Trimester in Hepatitis B Surface Antigen Positive Mothers With High Viral Load: A 10-year Prospective Study.
Topics: Antiviral Agents; DNA, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, | 2023 |
Clinical and Immunological Factors Associated with Postpartum Hepatic Flares in Immune-Tolerant Pregnant Women with Hepatitis B Virus Infection Treated with Telbivudine.
Topics: Alanine Transaminase; Antiviral Agents; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens; Hep | 2021 |
Safety and efficacy of telbivudine for chronic hepatitis B during the entire pregnancy: Long-term follow-up.
Topics: Antiviral Agents; Child Development; Child, Preschool; Female; Follow-Up Studies; Hepatitis B, Chron | 2017 |
Safety and efficacy of lamivudine or telbivudine started in early pregnancy for mothers with active chronic hepatitis B.
Topics: Adult; Antiviral Agents; Case-Control Studies; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis | 2018 |
Hepatitis B virus serosurvey and awareness of mother-to-child transmission among pregnant women in Shenyang, China: An observational study.
Topics: Adult; Antiviral Agents; China; Female; Health Knowledge, Attitudes, Practice; Hepatitis B e Antigen | 2018 |
Ending vertical transmission of hepatitis B: the third trimester intervention.
Topics: Female; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Male; P | 2014 |
Comparison of telbivudine versus lamivudine in interrupting perinatal transmission of hepatitis B virus.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant | 2014 |
Reduction of infectivity in chronic hepatitis B virus carriers among healthcare providers and pregnant women by antiviral therapy.
Topics: Adenine; Antiviral Agents; DNA, Viral; Female; Guanine; Health Personnel; Hepatitis B e Antigens; He | 2014 |
Growth and development of children prenatally exposed to telbivudine administered for the treatment of chronic hepatitis B in their mothers.
Topics: Adult; Ankyloglossia; Antiviral Agents; Body Mass Index; Body Weight; Child Development; China; Deli | 2015 |
Should Evidence-based Medicine Be Used to Design Clinical Practice Guidelines for the Prevention of Perinatal Transmission of Hepatitis B Virus From Hepatitis B e Antigen-Positive Mothers?
Topics: Antiviral Agents; Female; Hepatitis B; Humans; Infectious Disease Transmission, Vertical; Male; Preg | 2015 |
Tenofovir rescue therapy in pregnant females with chronic hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Apgar Score; Biomarkers; Birth Weight; China; DNA, Viral; Drug Res | 2015 |
[Clinical observation of telbivudine's antiviral efficacy and protection against mother-to-infant transmission of chronic hepatitis B during the first trimester of pregnancy].
Topics: Antiviral Agents; DNA, Viral; Female; Hepatitis A Vaccines; Hepatitis B e Antigens; Hepatitis B Vacc | 2015 |
[Predictive value of telbivudine in preventing mother-to-infant transmission of hepatitis B virus in pregnant women with high viremia].
Topics: Female; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Humans; Immunoglobuli | 2015 |
[Prevention of mother to child transmission of hepatitis B].
Topics: Adult; Antiviral Agents; Female; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B, Ch | 2015 |
[The safety of telbivudine in preventing mother-to-infant transmission of hepatitis B virus in pregnant women after discontinuation].
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, C | 2015 |
[Efficacy of combination antiviral therapy following childbirth in pregnant HBV carriers receiving telbivudine for prevention of mother-to-child transmission].
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Carrier State; DNA, Viral; Drug Therapy, Combinatio | 2015 |
Hepatic flare after telbivudine withdrawal and efficacy of postpartum antiviral therapy for pregnancies with chronic hepatitis B virus.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Administration Schedule; Female; Follow-Up Studi | 2017 |
[Telbivudine for prevention of perinatal transmission in pregnant women infected with hepatitis B virus in immune-tolerant phase: a study of efficacy and safety of drug withdrawal].
Topics: Antiviral Agents; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Humans; Infant; In | 2016 |
Telbivudine treatment of hepatitis B virus-infected pregnant women at different gestational stages for the prevention of mother-to-child transmission: Outcomes of telbivudine treatment during pregnancy.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Administration Schedule; Female; Hepatitis B, Chronic; | 2016 |
Long-term safety and efficacy of telbivudine in infants born to mothers treated during the second or third trimesters of pregnancy.
Topics: Adult; Antiviral Agents; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Female; | 2017 |
HBV treatment and pregnancy.
Topics: Female; Hepatitis B, Chronic; Humans; Infectious Disease Transmission, Vertical; Male; Nucleosides; | 2011 |
N-Methanocarbathymidine is more effective than acyclovir for treating neonatal herpes simplex virus infection in guinea pigs.
Topics: Acyclovir; Animals; Animals, Newborn; Antiviral Agents; Disease Models, Animal; Guinea Pigs; Herpes | 2011 |
Interruption of mother-to-infant transmission of hepatitis B: time to include selective antiviral prophylaxis?
Topics: Antiviral Agents; Developing Countries; Female; Hepatitis B; Humans; Infant; Infant, Newborn; Infect | 2012 |
The 2012 revised Dutch national guidelines for the treatment of chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Drug Approval; Drug Resistance, Viral; Female; Guanine; Hepatitis B, Chro | 2012 |
Rubella virus and human lymphocytes in culture.
Topics: Adult; Antigen-Antibody Reactions; Culture Techniques; DNA; Female; Humans; Infant; Infant, Newborn; | 1968 |